RNLXD (Renalytix) Research & Development: $1.20 Mil (TTM As of Dec. 2025)


RNLXD Renalytix PLC RNLXD
46 GF Score
Price $4.11
GF Value $10.82
! 3 Warning Signs
View Full Analysis

What is Renalytix Research & Development?

Renalytix RNLXD +0.46% 46 Research & Development is $1.20 Mil as of Dec. 2025. GuruFocus rates RNLXD with a GF Score™ of 46/100 and a GF Value™ of $10.82. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Renalytix's Research & Development for the six months ended in Dec. 2025 was $0.60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $1.20 Mil.

Renalytix  (OTCPK:RNLXD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Renalytix Research & Development Related Terms

Renalytix Research & Development Historical Data

* Premium members only.

The historical data trend for Renalytix's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Research & Development Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 0.00 14.65 14.30 5.10 0.90

Renalytix Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.30 0.60 0.60
RNLXD
46GF Score
Renalytix PLC RNLXD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.20 Mil mean?
Renalytix (RNLXD) has a Research & Development of $1.20 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Renalytix and its competitors.
Is Renalytix's Research & Development too high?
Renalytix's current Research & Development is $1.20 Mil. Overall, Renalytix has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Research & Development compare to VEEV and BTSG?
Renalytix's Research & Development of $1.20 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Renalytix and its competitors. Renalytix's current Research & Development is $1.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (RNLXD) has a current Research & Development of $1.20 Mil. The stock's GF Value™ is $10.82, compared to a current price of $4.11 — trading 62% below its estimated fair value. The current Research & Development is $1.20 Mil. Renalytix's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Renalytix (RNLXD), the current Research & Development is $1.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renalytix (RNLXD) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of $4.11 is trading 62% below its estimated GF Value™ of $10.82.

Key valuation signals for RNLXD:

  • Research & Development: $1.20 Mil
  • GF Value™: $10.82 vs. price of $4.11 (62% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score

Get the complete analysis for RNLXD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$10.82
GF Value